

www.tajpharma.com

Treatment for: Cardiovascular Risk Reduction

FDA Approves ZONTIVAS® (tablets contain 2.08 mg vorapaxar) Once-daily to Reduce the Risk of Heart Attacks and Stroke.

First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease

Once-daily
ZONTIVAS®
(vorapaxar) tablets 2.08 mg

Once-daily
ZONTIVAS®
(vorapaxar) tablets 2.08 mg

ZONTIVAS® (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist for the prevention of cardiovascular events in high risk patients.

ZONTIVAS® (vorapaxar), the first in a new class of drugs called protease-activated receptor-1 (PAR-1) antagonists.

It is an anti-platelet agent designed to inhibit the formation of blood clots. It is used for the secondary prevention of thrombotic cardiovascular events in high risk patients, reducing the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a history of heart attack or peripheral arterial disease.

ZONTIVAS® increases the risk of bleeding which may be life threatening, and the product label includes a Boxed Warning to alert health care professionals about this risk. It must not be used in people who have previously had a stroke, transient ischemic attack (TIA), or intracranial hemorrhage.

ZONTIVAS® is taken once daily, with or without food. **It should be should be prescribed with daily aspirin and/or clopidogrel.**

ZONTIVAS® is a prescription anti-platelet agent medicine used inhibit the formation of blood clots in people who have

- had a heart attack or
- reduced blood flow in their legs (peripheral arterial disease).

It is used with aspirin and/or clopidogrel to lower your chance of having another serious problem with your heart or blood vessels, such as heart attack, stroke, or death.

It is not known if this medicine is safe and effective in children.

Once-daily ZONTIVAS® tablets contain 2.08 mg vorapaxar, equivalent to 2.5 mg vorapaxar sulfate.

ZONTIVAS® should be used with daily aspirin and/or clopidogrel according to their indications or standard of care.

Food and Drug Administration (FDA) approved .Prescription Only (POM)

Once-daily
ZONTIVAS®
(vorapaxar) tablets 2.08 mg

A Taj Pharma™ India Product